Sharp Memorial Hospital, San Diego, La Jolla.
School of Medicine, University of California, San Diego, La Jolla.
Clin Infect Dis. 2019 Jan 1;68(1):157-164. doi: 10.1093/cid/ciy557.
The majority of patients with reported penicillin allergy are not allergic when tested or challenged. Penicillin allergy testing has been shown to significantly reduce annual healthcare expenditures. Data have emerged showing β-lactams have multidimensional antibacterial effects in vivo, far beyond what is appreciated in standard bacteriological susceptibility testing media. These include enhancing bacterial killing by the innate immune system. Supporting the clinical relevance of these secondary underappreciated effects are recent clinical and pharmacoeconomic analyses that show worse outcomes in patients with reported penicillin allergies who receive non-β-lactam antibiotics when compared to their non-penicillin-allergic counterparts. This is particularly relevant in the treatment of Staphylococcus aureus bacteremia. This article reviews the tremendous advantages offered by β-lactam therapy and makes a strong case that the debunking of false penicillin allergies through a detailed allergy history and penicillin allergy testing should be a vital component of antimicrobial stewardship practices.
大多数报告有青霉素过敏的患者在经过测试或挑战后并未过敏。青霉素过敏测试已被证明可显著降低年度医疗保健支出。有数据表明,β-内酰胺类药物在体内具有多维的抗菌作用,远远超出标准细菌药敏检测介质所了解的范围。这些作用包括增强固有免疫系统对细菌的杀伤作用。最近的临床和药物经济学分析支持了这些被低估的次要作用的临床相关性,这些分析表明,与非青霉素过敏患者相比,报告有青霉素过敏的患者在接受非β-内酰胺类抗生素治疗时,其治疗结果更差。这在金黄色葡萄球菌菌血症的治疗中尤为重要。本文综述了β-内酰胺类治疗带来的巨大优势,并强烈认为,通过详细的过敏史和青霉素过敏测试来揭穿虚假的青霉素过敏应该成为抗菌药物管理实践的重要组成部分。